Prevalencia, microbiología y patrones de sensibilidad a los antifúngicos de los aislamientos orales de Candida que colonizaban o infectaban a pacientes mexicanos con infección por VIH o sida y a personas sanas

Barchiesi, 1998, Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidiasis, J Antimicrob Chemother, 41, 541, 10.1093/jac/41.5.541 Barchiesi, 2002, Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy, J Antimicrob Chemother, 50, 999, 10.1093/jac/dkf233 Barchiesi, 1993, Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients, Eur J Epidemiol, 9, 455, 10.1007/BF00157408 Barturen, 1995, Variability in expression of antigens responsible for serotype specificity in Candida albicans, Microbiology, 141, 1535, 10.1099/13500872-141-7-1535 Barturen, 1996, Distribución de los serotipos de Candida albicans en aislamientos clínicos de personas inmunocompetentes e inmunosuprimidas, Rev Iberoam Micol, 13, 10 Bikandi, 1998, Rapid identification of Candida dubliniensis by indirect immunofluorescence based on differential localization of antigens on C. dubliniensis blastospores and Candida albicans germ tubes, J Clin Microbiol, 36, 2428, 10.1128/JCM.36.9.2428-2433.1998 Blignaut, 2002, Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals, Diagn Microbiol Infect Dis, 44, 169, 10.1016/S0732-8893(02)00440-6 Brawner, 1992, Serotype prevalence of Candida albicans from blood culture isolates, J Clin Microbiol, 30, 149, 10.1128/JCM.30.1.149-153.1992 Brawner, 1989, Oral Candida albicans isolates from non-hospitalized normal carriers, immunocompetent hospitalized patients and immunocompromised patients with or without acquired immunodeficiency syndrome, J Clin Microbiol, 27, 1335, 10.1128/JCM.27.6.1335-1341.1989 Cassone, 1999, In vitro and in vivo antiCandidal activity of human immunodeficiency virus protease inhibitors, J Infect Dis, 180, 448, 10.1086/314871 Ceballos, 1996, Prevalencia y distribución de las candidiasis orales en pacientes con SIDA establecido, Med Oral, 1, 6 Ceballos García, 1999, Prevalence of oral manifestations associated with human immunodeficiency virus infection in a homosexual population, Med Oral, 4, 470 Ceballos Salobreña, 1999, Resistencia in vitro a los antifúngicos en Candida albicans de pacientes infectados por el VIH con y sin candidiasis oral, Rev Iberoam Micol, 16, 194 Ceballos Salobreña, 2000, The influence of different risk behaviors in the appearance of oral candidiasis in AIDS patients, Med Oral, 5, 71 Ceballos-Salobreña, 1998, Oral lesions associated to human immunodeficiency virus infection in a series of 510 patients, Med Oral, 3, 199 Ceballos-Salobreña, 2004, The effect of antiretroviral therapy on the prevalence of HIV-associated oral candidiasis in a Spanish cohort, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 97, 345, 10.1016/j.tripleo.2003.09.016 CONASIDA. Panorama Epidemiológico del VIH/SIDA e ITS en México. Consejo Nacional para la prevención y control del VIH/SIDA, Secretaría de Salud, México. Dirección General de Epidemiología. Available at: http://www.salud.gob.mx/conasida. Contreras, 1994, Prevalence of Candida parapsilosis in the oral cavities of infants in Spain, Clin Infect Dis, 18, 480, 10.1093/clinids/18.3.480 Davey, 1998, Comparative evaluation of FUNGITEST and broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans, J Clin Microbiol, 36, 926, 10.1128/JCM.36.4.926-930.1998 De Bernardis, 1996, Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus, Infect Immun, 64, 466, 10.1128/IAI.64.2.466-471.1996 Diekema, 1999, In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY antimicrobial surveillance program in North America and Latin America, Antimicrob Agents Chemother, 43, 2236, 10.1128/AAC.43.9.2236 Diz Dios, 1999, Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 87, 437, 10.1016/S1079-2104(99)70242-8 Diz Dios, 2001, Changes in oropharyngeal colonization and infection by Candida albicans in Human immunodeficiency virus-infected patients, J Infect Dis, 183, 355, 10.1086/317920 Drouhet, 1975, [Sensitivity and resistance of pathogenic yeasts to 5-fluoropyrimidines. I. Relation between the phenotypes of resistance to 5-fluorocytosine, the serotype of Candida albicans and the ecology of various species of Candida of human origin], Ann Microbiol (Paris), 126B, 25 Gaitán-Cepeda, 2002, Prevalence of oral lesions in Mexican children with perinatally acquired HIV: association with immunologic status, viral load, and gender, AIDS Patient Care STDS, 16, 151, 10.1089/10872910252930858 Gottfredsson, 1999, Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization, J Infect Dis, 180, 534, 10.1086/314887 Hannula, 2001, Subgingival strains of Candida albicans in relation to geographical origin and occurrence of periodontal pathogenic bacteria, Oral Microbiol Immunol, 16, 113, 10.1034/j.1399-302x.2001.016002113.x Hannula, 1997, Phenotypic and genotypic characterization of oral yeasts from Finland and the United States, Oral Microbiol Immunol, 12, 358, 10.1111/j.1399-302X.1997.tb00739.x Hasenclever, 1963, Antigenic studies of Candida. IV. The relationship of the antigenic groups of Candida albicans to their isolation from various clinical specimens, Sabouraudia, 2, 201, 10.1080/00362176385190341 Klein, 2000, Oropharyngeal Candida colonization and human immunodeficiency virus type 1 infection, J Infect Dis, 181, 812, 10.1086/315290 Lehner, 1967, Oral candidiasis, Dent Pract, 17, 209 Martin, 1982, Frequency of Candida albicans serotypes in patients with denture-induced stomatitis and in normal denture wearers, J Clin Pathol, 35, 888, 10.1136/jcp.35.8.888 Martins, 1998, Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazoleresistant C. albicans in human immunodeficiency virus-infected patients, Clin Infect Dis, 27, 1291, 10.1086/515006 Martins, 1997, Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients, Clin Infect Dis, 25, 843, 10.1086/515554 McMullan-Vogel, 1999, Serotype distribution and secretory acid proteinase activity of Candida albicans isolated from the oral mucosa of patients with denture stomatitis, Oral Microbiol Immunol, 14, 183, 10.1034/j.1399-302X.1999.140307.x Morace, 1990, Epidemiological and clinical aspects of mycoses in patients with AIDS-related pathologies, Eur J Epidemiol, 6, 398, 10.1007/BF00151714 Mosca, 2003, Casein agar: a useful medium for differentiating Candida dubliniensis from Candida albicans, J Clin Microbiol, 41, 1259, 10.1128/JCM.41.3.1259-1262.2003 National Committee for Clinical Laboratory Standards Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard-Second Edition. NCCLS document M27-A2. Wayne, NCCLS, 2002. Odds, 1988 Odds, 1993, Resistance of yeasts to azolederivative antifungals, J Antimicrobial Chemother, 31, 463, 10.1093/jac/31.4.463 Pappas, 2004, Guidelines for treatment of candidiasis, Clin Infect Dis, 38, 161, 10.1086/380796 Pfaller, 1998, International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada and South America for the SENTRY program, J Clin Microbiol, 36, 1886, 10.1128/JCM.36.7.1886-1889.1998 Pinjon, 1998, Simple, inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicans, J Clin Microbiol, 36, 2093, 10.1128/JCM.36.7.2093-2095.1998 Quindós, 2004, In-vitro activity of 5-fluorocytosine against 1,021 Spanish clinical isolates of Candida and other medically important yeasts, Rev Iberoam Micol, 21, 63 Ramirez-Amador, 2003, The changing clinical spectrum of human immunodeficiency virus (HIV)-related oral lesions in 1,000 consecutive patients: A 12-year study in a referral center in Mexico, Medicine (Baltimore), 82, 39, 10.1097/00005792-200301000-00004 Samaranayake, 1990, Classification of oral candidiasis, 124 Sánchez Vargas LO, Ortiz-López NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Gaitán LA, Quindós G. Oral Candida isolates colonizing or infecting Mexican HIV-infected and healthy persons. J Clin Microbiol 2005; 43: in press. Sanglard, 2002, Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences, Lancet Infect Dis, 2, 73, 10.1016/S1473-3099(02)00181-0 Stallybrass, 1964, The incidence of the serological groups of Candida albicans in Southern England, J Hyg (Lond.), 62, 395, 10.1017/S0022172400040110 Stiller, 1982, Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States, Antimicrob Agents Chemother, 22, 482, 10.1128/AAC.22.3.482 Vargas, 2002, Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals, J Clin Microbiol, 40, 341, 10.1128/JCM.40.2.341-350.2002 Williams, 2000, Isolation and identification of Candida from the oral cavity, Oral Dis, 6, 3, 10.1111/j.1601-0825.2000.tb00314.x Willinger, 2000, Susceptibility testing of Candida species: comparison of NCCLS microdilution method with Fungitest®, Diagn Microbiol Infect Dis, 38, 11, 10.1016/S0732-8893(00)00172-3 Willinger, 2002, Multicenter comparison of Fungitest for susceptibility testing of Candida species, Diagn Microbiol Infect Dis, 44, 253, 10.1016/S0732-8893(02)00452-2 Witthuhn, 1999, Evaluation of the Fungitest kit by using strains from human immunodeficiency virus-infected patients: study of azole drug susceptibility, J Clin Microbiol, 3, 864, 10.1128/JCM.37.3.864-866.1999 Wroblewska, 2002, Epidemiology of clinical isolates of Candida albicans and their susceptibility to triazoles, Int J Antimicrob Agents, 20, 472, 10.1016/S0924-8579(02)00246-7 Xu, 2003, Geographical differences in human oral yeast flora, Clin Infect Dis, 36, 221, 10.1086/345672